Last reviewed · How we verify
Ticagrelor 90mg
At a glance
| Generic name | Ticagrelor 90mg |
|---|---|
| Also known as | Brilinta, brilique, Ticagrelor, Early versus late loading with Ticagrelol, Brilique |
| Sponsor | University of Arkansas |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ticagrelor Monotherapy After Stenting (PHASE2)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions (PHASE3)
- Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention (PHASE4)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke (PHASE3)
- DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor 90mg CI brief — competitive landscape report
- Ticagrelor 90mg updates RSS · CI watch RSS
- University of Arkansas portfolio CI